Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is poised for success with its lead candidate, cadisegliatin, as an adjunctive therapy for type 1 diabetes, which has Breakthrough Therapy Designation and is currently in a Phase 3 trial expected to complete enrollment by 3Q26. Beyond the core T1D population, cadisegliatin also shows potential in adolescents and in combination with hybrid closed-loop insulin delivery systems. With a strong clinical profile and increasing relevance in the T1D landscape, vTv’s stock has potential to reach new heights, leading us to increase our price target to $57.

Bears say

vTv Therapeutics is facing multiple challenges that could impact its future growth and financial performance. These include higher than expected operating expenses, potential delays in clinical trials, and stiff competition in the T1D market. Additionally, the company is dependent on third-party suppliers and faces potential manufacturing risks. While its lead candidate, cadisegliatin, shows promise as a metabolic adjunct, it may face challenges in complementing emerging curative modalities, and its efficacy may vary in different patient populations. Overall, the company's financial outlook may be negatively impacted by these factors, leading to a negative outlook on its stock.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.